Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onapristone - Context Therapeutics

Drug Profile

Onapristone - Context Therapeutics

Alternative Names: Apristor; AR-18; IVV-1001; Onapristone - Arno Therapeutics; Onapristone extended-release; ZK 299; ZK 98299

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Context Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Discontinued Breast cancer; Endometriosis; Pregnancy; Uterine cancer

Most Recent Events

  • 08 Oct 2019 Context Therapeutics signs a clinical trial collaboration agreement with Wisconsin Oncology Network (WON) for the conduction of a phase II trial in Breast cancer (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic-disease) (PO)
  • 08 Oct 2019 Context Therapeutics plans a phase III trial for Breast cancer
  • 07 Oct 2019 Context Therapeutics in collaboration with Wisconsin Oncology Network (WON) plans a first patient enrollment in phase II trial (Metastatic disease, combination therapy, Late-stage disease, Second-line therapy or greater) for Breast cancer (PO) in early 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top